TETON-2 Phase 3 Trial Shows Benefits of Inhaled Treprostinil in IPF A recent clinical trial shows inhaled treprostinil is associated with a smaller decline in forced vital capacity and fewer clinical worsening events compared with the placebo in IPF.

Inhaled #Treprostinil is associated with smaller decline in forced vital capacity and fewer clinical worsening events compared with placebo in patients with #IPF. Results from a multinational phase 3 clinical trial called TETON-2 (#NCT05255991)

Read more: https://bit.ly/485v0HC